




Belgian Cancer Registry

## CANCER FACT SHEET 2022

### CERVICAL CANCER

ICD-10 C53



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**HPV:** Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of cervical cancers.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Cervical cancer incidence: by region .....	5
1.1.1. Cervical cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022 .....	5
1.2. Cervical cancer incidence: by tumour stage .....	6
1.2.1. Cervical cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	6
1.2.2. Cervical cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	6
1.2.3. Cervical cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.4. Cervical cancer incidence by Human Papillomavirus infection: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
2. CANCER INCIDENCE TRENDS .....	8
2.1. Cervical cancer incidence trends: by region .....	8
2.1.1. Cervical cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	8
2.2. Cervical cancer incidence trends: by tumour stage .....	9
2.2.1. Cervical cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards .....	9
2.3. Cervical cancer incidence trends: by age group .....	10
2.3.1. Cervical cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	10
3. CANCER PREVALENCE .....	11
3.1. Cervical cancer prevalence: by region .....	11
3.1.1. Cervical cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022 .....	11
4. CANCER SURVIVAL .....	12
4.1. Cervical cancer survival: by region .....	12
4.1.1. Cervical cancer survival by region and age group: number at risk and net survival probabilities, 2013-2022 .....	12
4.2. Cervical cancer survival: by tumour stage .....	14
4.2.1. Cervical cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2013-2022 .....	14
4.2.2. Cervical cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2013-2022 .....	15
4.2.3. Cervical cancer survival by stage: number at risk and net survival probabilities, 2013-2022 .....	16
5. CANCER SURVIVAL TRENDS .....	17
5.1. Cervical cancer survival trends: by tumour stage .....	17
5.1.1. Cervical cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022 .....	17
6. CANCER MORTALITY .....	19

6.1. Cervical cancer mortality: by region.....	19
6.1.1. Cervical cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021.....	19
7. CANCER MORTALITY TRENDS.....	20
7.1. Cervical cancer mortality trends: by region.....	20
7.1.1. Cervical cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021.....	20
8. CARCINOMA IN SITU INCIDENCE.....	21
8.1. Cervical carcinoma in situ incidence: by region.....	21
8.1.1. Cervical carcinoma in situ incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	21
9. CARCINOMA IN SITU INCIDENCE TRENDS.....	22
9.1. Cervical carcinoma in situ incidence trends: by region.....	22
9.1.1. Cervical carcinoma in situ incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	22
9.2. Cervical carcinoma in situ incidence trends: by age group.....	24
9.2.1. Cervical carcinoma in situ incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	24



# 1. CANCER INCIDENCE



## 1.1. Cervical cancer incidence: by region

1.1.1. Cervical cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Females																						
<b>Belgium</b>	0	0	1	1	2	7	36	61	87	71	67	78	70	52	33	35	18	17	4	1	641	11.0
	[0.0]	[0.0]	[0.3]	[0.3]	[0.6]	[1.9]	[9.4]	[16.3]	[23.0]	[19.3]	[17.3]	[19.6]	[18.6]	[15.6]	[11.2]	[15.1]	[10.1]	[12.6]	[5.8]	[4.9]	[10.9]	(10.2; 11.9)
Brussels	0	0	0	1	0	1	2	8	9	5	8	11	4	5	3	2	3	1	0	0	63	11.4
	[0.0]	[0.0]	[0.0]	[2.9]	[0.0]	[1.8]	[3.8]	[16.9]	[20.0]	[12.4]	[21.5]	[32.6]	[13.4]	[20.1]	[14.1]	[11.6]	[23.0]	[9.9]	[0.0]	[0.0]	[10.1]	(8.5; 14.2)
Flanders	0	0	1	0	0	4	20	30	49	43	32	32	42	32	18	21	12	8	4	1	349	10.3
	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[2.0]	[9.5]	[14.3]	[22.6]	[20.8]	[14.2]	[13.4]	[18.7]	[16.2]	[10.4]	[14.7]	[10.7]	[9.4]	[9.4]	[8.3]	[10.3]	(9.2; 11.4)
Wallonia	0	0	0	0	2	2	14	23	29	23	27	35	24	15	12	12	3	8	0	0	229	12.4
	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.9]	[11.8]	[19.8]	[24.9]	[19.1]	[21.7]	[27.6]	[19.6]	[13.6]	[12.0]	[16.9]	[5.6]	[20.3]	[0.0]	[0.0]	[12.2]	(10.8; 14.0)

## 1.2. Cervical cancer incidence: by tumour stage

1.2.1. Cervical cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages	
I	88 [4.7]	40 [3.4]	23 [1.8]	151 [2.6]	2.7 (2.2; 3.1)
II	29 [1.6]	35 [3.0]	31 [2.5]	95 [1.6]	1.6 (1.3; 1.9)
III	44 [2.4]	58 [5.0]	36 [2.9]	138 [2.3]	2.4 (2.0; 2.8)
IV	14 [0.8]	30 [2.6]	42 [3.3]	86 [1.5]	1.4 (1.1; 1.7)
X/NA	87 [4.7]	52 [4.5]	28 [2.2]	171 [2.9]	3.0 (2.5; 3.4)

1.2.2. Cervical cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages	
I	154 [8.3]	74 [6.4]	24 [1.9]	254 [4.3]	4.5 (3.9; 5.0)
II	9 [0.5]	8 [0.7]	4 [0.3]	21 [0.4]	0.4 (0.2; 0.5)
III	11 [0.6]	12 [1.0]	0 [0.0]	23 [0.4]	0.4 (0.2; 0.6)
IV	2 [0.1]	6 [0.5]	8 [0.6]	16 [0.3]	0.3 (0.1; 0.4)
X/NA	86 [4.6]	115 [9.9]	124 [9.8]	327 [5.6]	5.5 (4.9; 6.1)

1.2.3. Cervical cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages	
I	156 [8.4]	76 [6.5]	30 [2.4]	264 [4.5]	4.6 (4.1; 5.2)
II	31 [1.7]	33 [2.8]	29 [2.3]	93 [1.6]	1.6 (1.3; 1.9)
III	49 [2.6]	64 [5.5]	36 [2.9]	149 [2.5]	2.6 (2.2; 3.0)
IV	14 [0.8]	29 [2.5]	46 [3.6]	89 [1.5]	1.5 (1.2; 1.8)
X/NA	12 [0.6]	13 [1.1]	19 [1.5]	46 [0.8]	0.8 (0.5; 1.0)

1.2.4. Cervical cancer incidence by Human Papillomavirus infection: number of new diagnoses, crude and age-standardised incidence rates, 2022

HPV status	N[CR]				ESR2013 (95%CI)
	25-49	50-64	65+	All ages	
HPV+	125 [6.7]	99 [8.5]	57 [4.5]	281 [4.8]	4.9 (4.3; 5.4)
HPV-	10 [0.5]	6 [0.5]	9 [0.7]	25 [0.4]	0.4 (0.3; 0.6)
Unregistered	60 [3.2]	56 [4.8]	47 [3.7]	165 [2.8]	2.8 (2.4; 3.3)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Cervical cancer incidence trends: by region

2.1.1. *Cervical cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	629	634	589	688	634	594	604	626	683	635	665	648	646	633	642	611	599	640	641			
	<b>CR</b>	11.8	11.9	11.0	12.7	11.6	10.8	10.9	11.2	12.1	11.2	11.7	11.4	11.3	11.0	11.1	10.5	10.3	11.0	10.9			
	<b>ESR2013</b>	11.9	12.0	11.0	12.8	11.7	10.9	10.9	11.3	12.3	11.4	11.7	11.5	11.5	11.1	11.2	10.6	10.4	11.0	11.0	-0.5 (-0.9; -0.1)	2004-2022	
Brussels	<b>N</b>	62	62	78	72	62	74	61	60	67	72	59	54	68	54	60	54	58	40	63			
	<b>CR</b>	11.9	11.9	14.7	13.5	11.4	13.4	10.8	10.4	11.4	12.1	9.9	9.0	11.2	8.9	9.8	8.8	9.3	6.4	10.1			
	<b>ESR2013</b>	12.7	12.6	15.6	14.9	12.4	14.6	11.9	11.0	13.0	13.4	11.1	10.2	12.7	9.7	10.9	10.1	10.3	7.1	11.4	-2.3 (-3.4; -1.2)	2004-2022	
Flanders	<b>N</b>	366	389	344	390	362	350	332	327	370	336	340	362	349	363	350	340	329	362	349			
	<b>CR</b>	12.0	12.7	11.2	12.6	11.6	11.1	10.5	10.2	11.5	10.4	10.5	11.1	10.7	11.0	10.6	10.2	9.8	10.8	10.3			
	<b>ESR2013</b>	11.9	12.6	11.0	12.5	11.4	11.1	10.2	10.1	11.5	10.4	10.3	11.1	10.6	10.9	10.4	10.1	9.8	10.6	10.3	-0.9 (-1.3; -0.4)	2004-2022	
Wallonia	<b>N</b>	201	183	167	226	210	170	211	239	246	227	266	232	229	216	232	217	212	238	229			
	<b>CR</b>	11.5	10.5	9.5	12.8	11.8	9.5	11.7	13.2	13.5	12.4	14.5	12.6	12.4	11.7	12.5	11.7	11.4	12.8	12.2			
	<b>ESR2013</b>	11.8	10.7	9.6	13.0	12.1	9.6	11.9	13.4	13.7	12.7	14.7	13.0	12.8	11.9	12.6	11.9	11.6	13.0	12.4	0.6 (-0.2; 1.5)	2004-2022	
																					2.2 (0.6; 3.9)	2004-2014	
																						-1.4 (-3.4; 0.7)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.





## 2.3. Cervical cancer incidence trends: by age group

2.3.1. Cervical cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period
<b>15-24 N</b>	2	4	2	6	3	4	4	3	4	4	4	1	3	3	2	1	3	1	3			
<b>CR</b>	0.3	0.6	0.3	0.9	0.5	0.6	0.6	0.5	0.6	0.6	0.6	0.2	0.5	0.5	0.3	0.2	0.5	0.2	0.5			
<b>ESR2013</b>	0.3	0.7	0.3	1.0	0.5	0.6	0.6	0.5	0.6	0.6	0.6	0.2	0.5	0.5	0.3	0.2	0.5	0.2	0.5	-4.0	(-8.0; 0.2)	2004-2022
<b>25-49 N</b>	300	320	289	320	302	270	284	265	304	276	282	321	271	247	256	236	245	260	262			
<b>CR</b>	16.2	17.3	15.6	17.3	16.3	14.5	15.3	14.2	16.3	14.8	15.2	17.3	14.6	13.3	13.8	12.7	13.2	14.0	14.1			
<b>ESR2013</b>	16.1	17.2	15.5	17.2	16.2	14.5	15.3	14.2	16.4	15.0	15.4	17.5	14.8	13.6	14.1	13.0	13.5	14.4	14.4	-1.0	(-1.6; -0.4)	2004-2022
<b>50-64 N</b>	153	159	150	192	153	159	162	181	185	201	204	162	199	223	204	205	194	205	215			
<b>CR</b>	16.7	17.1	15.7	19.6	15.2	15.5	15.4	16.9	17.1	18.4	18.5	14.5	17.6	19.6	17.8	17.8	16.8	17.7	18.5			
<b>ESR2013</b>	16.8	17.1	15.7	19.4	15.2	15.4	15.4	16.9	17.1	18.4	18.5	14.5	17.6	19.5	17.8	17.8	16.8	17.7	18.5	0.5	(-0.2; 1.3)	2004-2022
<b>65+ N</b>	174	151	148	170	176	161	154	177	190	154	175	164	173	160	180	169	157	174	160			
<b>CR</b>	16.7	14.3	14.0	16.1	16.6	15.1	14.3	16.3	17.2	13.7	15.4	14.2	14.8	13.5	15.0	13.9	12.8	14.0	12.7			
<b>ESR2013</b>	16.4	14.4	13.6	16.2	16.7	15.4	13.8	16.1	17.5	14.2	15.0	14.5	15.5	13.5	15.1	14.2	12.9	13.9	12.9	-0.8	(-1.5; -0.1)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

### 3. CANCER PREVALENCE



#### 3.1. Cervical cancer prevalence: by region

3.1.1. *Cervical cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Females			
		1-year	5-year	10-year	15-year
Belgium	<b>N</b>	583	2,385	4,351	5,956
	<b>CR</b>	9.8	40.2	73.3	100
	<b>ESR2013</b>	10.0	40.9	74.6	101.6
Brussels	<b>N</b>	60	210	389	529
	<b>CR</b>	9.5	33.2	61.5	83.6
	<b>ESR2013</b>	10.7	37.7	70.8	97.1
Flanders	<b>N</b>	312	1,323	2,433	3,354
	<b>CR</b>	9.1	38.7	71.1	98.0
	<b>ESR2013</b>	9.2	38.9	71.4	97.6
Wallonia	<b>N</b>	211	852	1,529	2,073
	<b>CR</b>	11.2	45.3	81.3	110.2
	<b>ESR2013</b>	11.4	46.0	82.4	111.3



### 4.1. Cervical cancer survival: by region

#### 4.1.1. Cervical cancer survival by region and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Females						
Belgium	All ages	6,304	88.4% (87.6%; 89.2%)	74.9% (73.7%; 76.1%)	69.9% (68.5%; 71.2%)	65.1% (62.9%; 67.4%)
	15-24	25	N<50	N<50	N<50	N<50
	25-49	2,633	96.4% (95.6%; 97.1%)	87.7% (86.4%; 89.0%)	84.6% (83.1%; 86.1%)	81.7% (79.8%; 83.6%)
	50-64	1,992	90.1% (88.7%; 91.4%)	74.3% (72.3%; 76.4%)	68.4% (66.1%; 70.7%)	62.2% (59.2%; 65.4%)
	65+	1,655	73.5% (71.3%; 75.9%)	54.9% (52.1%; 57.8%)	47.8% (44.6%; 51.3%)	41.4% (34.9%; 49.0%)
Brussels	All ages	572	90.8% (88.3%; 93.3%)	76.4% (72.5%; 80.5%)	69.2% (64.8%; 73.9%)	67.7% (62.3%; 73.7%)
	15-24	4	N<50	N<50	N<50	N<50
	25-49	255	95.7% (93.2%; 98.3%)	85.4% (81.0%; 90.0%)	81.0% (76.0%; 86.4%)	78.1% (72.2%; 84.4%)
	50-64	183	91.6% (87.6%; 95.8%)	76.0% (69.8%; 82.8%)	67.4% (60.2%; 75.5%)	64.8% (56.6%; 74.2%)
	65+	131	79.6% (72.4%; 87.6%)	58.8% (48.7%; 71.1%)	48.0% (37.6%; 61.4%)	50.7% (36.4%; 70.6%)
Flanders	All ages	3,452	88.8% (87.7%; 89.9%)	76.1% (74.5%; 77.7%)	71.8% (70.0%; 73.6%)	67.0% (63.7%; 70.6%)
	15-24	13	N<50	N<50	N<50	N<50
	25-49	1,421	97.1% (96.3%; 98.0%)	89.0% (87.3%; 90.7%)	86.0% (84.1%; 88.0%)	83.7% (81.2%; 86.2%)
	50-64	1,078	91.5% (89.8%; 93.2%)	76.9% (74.3%; 79.6%)	71.7% (68.7%; 74.8%)	66.3% (62.4%; 70.5%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>65+</b>	940	72.9% (69.9%; 76.1%)	55.4% (51.7%; 59.2%)	49.9% (45.6%; 54.5%)	42.1% (32.9%; 53.7%)
Wallonia	<b>All ages</b>	2,281	87.2% (85.8%; 88.6%)	72.7% (70.7%; 74.7%)	67.2% (64.9%; 69.5%)	61.6% (58.4%; 64.9%)
	<b>15-24</b>	8	N<50	N<50	N<50	N<50
	<b>25-49</b>	958	95.4% (94.0%; 96.7%)	86.4% (84.2%; 88.7%)	83.5% (81.0%; 86.0%)	79.7% (76.4%; 83.2%)
	<b>50-64</b>	731	87.6% (85.2%; 90.0%)	70.1% (66.7%; 73.7%)	63.7% (59.9%; 67.6%)	55.8% (50.7%; 61.3%)
	<b>65+</b>	584	73.2% (69.4%; 77.1%)	53.2% (48.7%; 58.2%)	44.5% (39.2%; 50.4%)	38.0% (29.9%; 48.3%)

## 4.2. Cervical cancer survival: by tumour stage

### 4.2.1. Cervical cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>All</b>	6,304	88.4% (87.6%; 89.2%)	79.3% (78.3%; 80.4%)	74.9% (73.7%; 76.1%)	71.8% (70.5%; 73.1%)	69.9% (68.5%; 71.2%)	65.1% (62.9%; 67.4%)
<b>I</b>	1,188	98.5% (97.6%; 99.3%)	95.2% (93.8%; 96.7%)	93.6% (92.0%; 95.3%)	91.8% (89.8%; 93.8%)	90.7% (88.5%; 93.0%)	84.8% (77.8%; 92.5%)
<b>II</b>	828	94.8% (93.1%; 96.5%)	86.9% (84.3%; 89.5%)	80.4% (77.2%; 83.8%)	74.7% (71.0%; 78.6%)	72.4% (68.4%; 76.7%)	62.9% (55.3%; 71.7%)
<b>III</b>	1,128	87.2% (85.2%; 89.3%)	73.4% (70.7%; 76.2%)	66.4% (63.5%; 69.6%)	61.4% (58.2%; 64.7%)	58.6% (55.2%; 62.1%)	50.9% (45.8%; 56.7%)
<b>IV</b>	752	56.0% (52.5%; 59.8%)	34.5% (31.1%; 38.2%)	26.8% (23.6%; 30.4%)	23.5% (20.4%; 27.1%)	20.9% (17.7%; 24.7%)	13.8% (9.1%; 21.0%)
<b>X/NA</b>	2,421	91.9% (90.7%; 93.0%)	85.4% (83.9%; 87.0%)	82.3% (80.6%; 84.0%)	80.3% (78.5%; 82.1%)	78.6% (76.7%; 80.6%)	76.5% (73.8%; 79.4%)

4.2.2. Cervical cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>All</b>	6,304	88.4% (87.6%; 89.2%)	79.3% (78.3%; 80.4%)	74.9% (73.7%; 76.1%)	71.8% (70.5%; 73.1%)	69.9% (68.5%; 71.2%)	65.1% (62.9%; 67.4%)
<b>I</b>	2,445	99.5% (99.2%; 99.9%)	97.9% (97.2%; 98.6%)	96.5% (95.6%; 97.5%)	95.3% (94.2%; 96.4%)	94.4% (93.2%; 95.7%)	91.3% (88.6%; 94.1%)
<b>II</b>	273	93.2% (90.1%; 96.5%)	81.3% (76.3%; 86.5%)	77.5% (72.1%; 83.2%)	72.5% (66.6%; 78.8%)	70.5% (64.3%; 77.2%)	65.1% (56.3%; 75.3%)
<b>III</b>	441	95.6% (93.5%; 97.7%)	85.8% (82.4%; 89.3%)	80.1% (76.2%; 84.2%)	74.9% (70.6%; 79.5%)	70.3% (65.5%; 75.4%)	66.6% (60.9%; 72.7%)
<b>IV</b>	157	63.1% (55.9%; 71.2%)	38.7% (31.6%; 47.3%)	32.9% (26.0%; 41.5%)	27.5% (21.0%; 36.0%)	25.1% (18.7%; 33.6%)	16.0% (10.0%; 25.7%)
<b>X/NA</b>	3,000	79.1% (77.6%; 80.7%)	65.1% (63.3%; 67.0%)	58.3% (56.4%; 60.3%)	54.3% (52.3%; 56.4%)	52.1% (50.0%; 54.4%)	46.3% (42.6%; 50.2%)

4.2.3. Cervical cancer survival by stage: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>All</b>	6,304	88.4% (87.6%; 89.2%)	79.3% (78.3%; 80.4%)	74.9% (73.7%; 76.1%)	71.8% (70.5%; 73.1%)	69.9% (68.5%; 71.2%)	65.1% (62.9%; 67.4%)
<b>I</b>	2,582	99.1% (98.6%; 99.6%)	96.9% (96.1%; 97.7%)	95.4% (94.3%; 96.4%)	94.0% (92.8%; 95.2%)	93.0% (91.6%; 94.3%)	89.3% (86.0%; 92.7%)
<b>II</b>	874	94.2% (92.5%; 96.0%)	86.0% (83.4%; 88.6%)	80.0% (76.9%; 83.3%)	74.8% (71.2%; 78.6%)	72.8% (68.9%; 76.9%)	65.5% (58.4%; 73.5%)
<b>III</b>	1,328	88.9% (87.2%; 90.7%)	76.7% (74.3%; 79.1%)	70.1% (67.4%; 72.8%)	65.3% (62.4%; 68.2%)	61.8% (58.8%; 65.0%)	55.0% (50.6%; 59.8%)
<b>IV</b>	797	56.4% (53.0%; 60.1%)	34.7% (31.5%; 38.4%)	27.0% (23.9%; 30.5%)	23.3% (20.3%; 26.8%)	20.9% (17.8%; 24.5%)	14.4% (9.9%; 21.0%)
<b>X/NA</b>	739	77.7% (74.6%; 80.9%)	62.8% (59.3%; 66.7%)	57.0% (53.2%; 61.0%)	54.0% (50.2%; 58.2%)	52.3% (48.2%; 56.8%)	50.4% (45.4%; 55.9%)



## 5. CANCER SURVIVAL TRENDS



### 5.1. Cervical cancer survival trends: by tumour stage

#### 5.1.1. Cervical cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>All</b>	3,124	86.5% (85.2%; 87.8%)	71.8% (70.1%; 73.5%)	66.8% (65.0%; 68.6%)
	<b>I</b>	1,271	98.6% (97.8%; 99.4%)	93.9% (92.4%; 95.5%)	91.0% (89.1%; 92.9%)
	<b>II</b>	327	91.7% (88.4%; 95.0%)	71.4% (66.1%; 77.0%)	64.7% (58.8%; 71.1%)
	<b>III</b>	490	86.9% (83.8%; 90.1%)	59.3% (54.9%; 64.1%)	50.8% (46.2%; 55.9%)
	<b>IV</b>	305	52.6% (47.2%; 58.6%)	26.8% (22.1%; 32.4%)	21.8% (17.4%; 27.2%)
	<b>X/NA</b>	733	77.1% (73.9%; 80.3%)	60.8% (57.1%; 64.7%)	55.2% (51.3%; 59.4%)
<b>2013-2017</b>	<b>All</b>	3,205	88.1% (86.9%; 89.3%)	74.3% (72.7%; 76.0%)	69.5% (67.7%; 71.3%)
	<b>I</b>	1,306	99.0% (98.3%; 99.7%)	94.6% (93.2%; 96.1%)	92.7% (91.0%; 94.5%)
	<b>II</b>	426	94.4% (91.9%; 96.9%)	78.9% (74.5%; 83.5%)	71.6% (66.6%; 77.1%)
	<b>III</b>	611	88.8% (86.2%; 91.5%)	70.3% (66.6%; 74.3%)	60.6% (56.6%; 65.0%)
	<b>IV</b>	348	53.9% (48.8%; 59.5%)	24.8% (20.5%; 29.9%)	20.2% (16.2%; 25.2%)
	<b>X/NA</b>	521	77.7% (74.1%; 81.5%)	57.5% (53.2%; 62.3%)	52.6% (48.0%; 57.6%)
<b>2018-2022</b>	<b>All</b>	3,099	88.7% (87.5%; 89.9%)	75.5% (73.8%; 77.2%)	70.1% (67.8%; 72.4%)
	<b>I</b>	1,276	99.1% (98.5%; 99.8%)	96.2% (94.8%; 97.6%)	92.8% (90.6%; 95.1%)
	<b>II</b>	448	94.1% (91.6%; 96.6%)	81.7% (77.2%; 86.4%)	74.2% (68.3%; 80.7%)
	<b>III</b>	717	89.1% (86.7%; 91.5%)	69.7% (65.9%; 73.6%)	64.1% (59.6%; 69.0%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>IV</b>	449	58.4% (54.0%; 63.3%)	28.7% (24.4%; 33.7%)	20.1% (15.5%; 26.0%)
	<b>X/NA</b>	218	77.7% (72.1%; 83.8%)	55.9% (48.9%; 64.0%)	51.0% (41.0%; 63.5%)

## 6. CANCER MORTALITY



### 6.1. Cervical cancer mortality: by region

6.1.1. Cervical cancer mortality\* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
<b>Belgium</b>	0	0	0	0	0	3	4	9	5	7	14	21	14	13	22	10	23	13	2	4	164	2.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.1]	[2.4]	[1.3]	[1.9]	[3.6]	[5.2]	[3.8]	[4.0]	[7.4]	[4.7]	[12.4]	[9.6]	[3.0]	[20.8]	[2.8]	(2.2; 3.0)
Brussels	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1	1	0	2	7	1.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[0.0]	[0.0]	[0.0]	[0.0]	[3.4]	[0.0]	[4.6]	[0.0]	[7.3]	[9.8]	[0.0]	[102.2]	[1.1]	(0.3; 2.0)
Flanders	0	0	0	0	0	3	4	6	4	4	10	14	8	8	16	6	15	9	2	2	111	3.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.5]	[1.9]	[2.9]	[1.9]	[1.9]	[4.4]	[5.9]	[3.6]	[4.1]	[9.2]	[4.5]	[12.9]	[10.6]	[5.0]	[17.8]	[3.3]	(2.4; 3.6)
Wallonia	0	0	0	0	0	0	0	2	1	3	4	7	5	5	5	4	7	3	0	0	46	2.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[0.9]	[2.4]	[3.2]	[5.5]	[4.1]	[4.6]	[5.0]	[6.3]	[12.7]	[7.5]	[0.0]	[0.0]	[2.5]	(1.7; 3.1)

## 7. CANCER MORTALITY TRENDS



### 7.1. Cervical cancer mortality trends: by region

7.1.1. Cervical cancer mortality\* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	189	170	162	162	187	197	163	197	179	176	157	161	147	170	174	143	144	164		
	<b>CR</b>	3.6	3.2	3.0	3.0	3.4	3.6	2.9	3.5	3.2	3.1	2.8	2.8	2.6	3.0	3.0	2.5	2.5	2.8		
	<b>ESR2013</b>	3.6	3.2	3.0	3.0	3.4	3.6	3.0	3.4	3.1	3.1	2.7	2.7	2.4	2.9	2.9	2.3	2.3	2.6	-2.0 (-2.8; -1.2)	2004-2021
Brussels	<b>N</b>	22	10	15	18	16	27	12	24	11	15	10	12	14	16	17	6	14	7		
	<b>CR</b>	4.2	1.9	2.8	3.4	3.0	4.9	2.1	4.2	1.9	2.5	1.7	2.0	2.3	2.6	2.8	1.0	2.3	1.1		
	<b>ESR2013</b>	4.7	2.0	3.1	3.9	3.1	5.8	2.5	4.6	2.3	3.2	1.8	2.5	2.7	2.9	3.2	1.0	2.6	1.1	-4.7 (-8.2; -1.0)	2004-2021
Flanders	<b>N</b>	127	117	110	103	129	122	110	120	129	107	103	93	86	105	106	87	91	111		
	<b>CR</b>	4.2	3.8	3.6	3.3	4.1	3.9	3.5	3.8	4.0	3.3	3.2	2.9	2.6	3.2	3.2	2.6	2.7	3.3		
	<b>ESR2013</b>	4.2	3.8	3.5	3.3	4.0	3.8	3.4	3.5	3.7	3.2	3.0	2.6	2.4	3.0	2.9	2.4	2.4	3.0	-2.8 (-3.8; -1.8)	2004-2021
Wallonia	<b>N</b>	40	43	37	41	42	48	41	53	39	54	44	56	47	49	51	50	39	46		
	<b>CR</b>	2.3	2.5	2.1	2.3	2.4	2.7	2.3	2.9	2.1	3.0	2.4	3.0	2.5	2.6	2.8	2.7	2.1	2.5		
	<b>ESR2013</b>	2.2	2.5	2.1	2.4	2.4	2.7	2.4	2.9	2.1	2.9	2.3	3.1	2.5	2.7	2.7	2.6	2.0	2.4	0.3 (-0.9; 1.5)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 8. CARCINOMA IN SITU INCIDENCE



### 8.1. Cervical carcinoma in situ incidence: by region

8.1.1. *Cervical carcinoma in situ incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Females																						
<b>Belgium</b>	0	0	0	9	229	943	1,315	1,133	979	692	480	234	163	94	36	28	11	7	0	0	6,353	112.8
	[0.0]	[0.0]	[0.0]	[2.8]	[69.2]	[261.2]	[343.3]	[303.6]	[258.8]	[188.4]	[124.1]	[58.7]	[43.3]	[28.3]	[12.2]	[12.1]	[6.2]	[5.2]	[0.0]	[0.0]	[108.1]	(110.0; 115.6)
Brussels	0	0	0	0	13	118	165	93	78	59	28	11	9	9	5	2	0	0	0	0	590	84.2
	[0.0]	[0.0]	[0.0]	[0.0]	[32.7]	[216.9]	[310.8]	[196.7]	[173.4]	[146.5]	[75.1]	[32.6]	[30.3]	[36.1]	[23.4]	[11.6]	[0.0]	[0.0]	[0.0]	[0.0]	[94.8]	(77.2; 91.1)
Flanders	0	0	0	5	152	656	789	682	639	410	300	153	96	55	23	14	6	6	0	0	3,986	125.4
	[0.0]	[0.0]	[0.0]	[2.9]	[83.6]	[330.3]	[373.7]	[324.8]	[294.5]	[198.2]	[133.1]	[64.2]	[42.8]	[27.8]	[13.2]	[9.8]	[5.4]	[7.0]	[0.0]	[0.0]	[117.9]	(121.5; 129.3)
Wallonia	0	0	0	4	64	169	361	358	262	223	152	70	58	30	8	12	5	1	0	0	1,777	101.1
	[0.0]	[0.0]	[0.0]	[3.7]	[58.5]	[156.5]	[303.9]	[308.8]	[225.3]	[185.6]	[122.3]	[55.2]	[47.4]	[27.3]	[8.0]	[16.9]	[9.4]	[2.5]	[0.0]	[0.0]	[95.0]	(96.4; 105.8)

## 9. CARCINOMA IN SITU INCIDENCE TRENDS



### 9.1. Cervical carcinoma in situ incidence trends: by region

9.1.1. *Cervical carcinoma in situ incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	<b>N</b>	1,792	1,702	1,895	2,160	2,420	2,505	2,647	3,210	3,892	3,742	4,385	4,751	5,098	6,181	6,315	6,937	5,983	6,473	6,353			
	<b>CR</b>	33.8	31.9	35.3	40.0	44.5	45.7	47.9	57.5	69.2	66.2	77.3	83.3	89.0	107.4	109.3	119.5	102.6	110.8	108.1			
	<b>ESR2013</b>	32.9	31.3	34.9	39.8	44.3	45.7	48.2	58.0	70.1	67.2	78.7	85.2	91.4	110.7	112.6	123.5	106.6	115.4	112.8	8.0 (7.3; 8.6)	2004-2022	
																					10.4 (9.5; 11.3)	2004-2017	
																						1.9 (-0.5; 4.4)	2018-2022
Brussels	<b>N</b>	289	264	277	347	372	293	394	425	563	499	538	502	582	665	595	704	567	641	590			
	<b>CR</b>	55.6	50.5	52.4	64.9	68.6	53.1	70.0	73.7	96.1	84.2	90.1	83.3	95.7	109.2	97.2	114.3	91.4	103.2	94.8			
	<b>ESR2013</b>	50.5	45.0	48.0	58.2	61.4	47.6	62.3	64.4	83.9	73.3	78.7	73.5	84.0	95.3	84.9	99.9	81.7	91.7	84.2	4.0 (3.0; 5.0)	2004-2022	
																					5.8 (3.9; 7.8)	2004-2014	
																						1.7 (-0.7; 4.1)	2015-2022
Flanders	<b>N</b>	1,018	965	1,067	1,409	1,563	1,603	1,596	1,884	2,187	2,065	2,513	2,590	2,872	3,581	3,906	4,148	3,702	3,941	3,986			
	<b>CR</b>	33.4	31.5	34.6	45.4	50.1	51.0	50.4	59.0	68.0	63.9	77.4	79.4	87.6	108.7	117.9	124.6	110.6	117.3	117.9			
	<b>ESR2013</b>	32.5	30.9	34.3	45.4	50.3	51.6	51.4	60.4	70.0	66.0	80.4	83.0	91.8	114.1	124.1	131.3	117.3	124.6	125.4	8.6 (7.7; 9.4)	2004-2022	
																						10.2 (8.9; 11.6)	2004-2016
																						5.3 (2.5; 8.2)	2017-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Wallonia <b>N</b>	485	473	551	404	485	609	657	901	1,142	1,178	1,334	1,659	1,644	1,935	1,814	2,085	1,714	1,891	1,777			
<b>CR</b>	27.9	27.1	31.4	22.8	27.3	34.1	36.5	49.7	62.7	64.4	72.7	90.2	89.1	104.6	97.8	112.2	92.0	101.5	95.0			
<b>ESR2013</b>	27.8	27.3	31.7	23.2	27.9	35.0	37.7	51.5	65.1	67.1	75.9	94.4	93.6	110.4	103.1	118.6	97.7	108.0	101.1	9.1 (7.6; 10.7)	2004-2022	
																				13.2 (11.1; 15.4)	2004-2017	
																					-0.8 (-6.3; 5.0)	2018-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 9.2. Cervical carcinoma in situ incidence trends: by age group

9.2.1. Cervical carcinoma in situ incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period		
<b>15-24</b>	<b>N</b>	143	127	130	168	203	221	235	288	320	301	297	275	267	324	309	312	271	268	238				
	<b>CR</b>	23.1	20.4	20.8	26.6	31.8	34.3	36.3	44.1	48.8	45.9	45.4	42.3	41.2	50.5	48.5	49.1	42.4	41.9	36.8				
	<b>ESR2013</b>	23.3	20.7	21.3	27.5	33.0	35.3	37.1	44.5	48.7	45.3	44.8	41.8	41.1	50.6	48.7	49.5	42.9	42.4	37.5	4.2 (3.4; 5.1)		2004-2022	
																					11.3 (9.0; 13.6)		2004-2012	
																								2013-2022
<b>25-49</b>	<b>N</b>	1,460	1,406	1,569	1,741	1,966	2,023	2,107	2,581	3,182	3,014	3,622	3,904	4,197	5,039	5,177	5,626	4,853	5,210	5,062				
	<b>CR</b>	78.8	76.0	84.7	93.9	105.9	108.9	113.4	138.6	170.9	162.0	195.2	211.0	226.7	272.0	279.0	302.7	260.8	280.1	271.7				
	<b>ESR2013</b>	78.7	76.2	85.1	94.6	106.5	109.7	114.1	139.3	171.5	162.2	195.0	210.2	225.7	270.9	276.9	300.6	259.4	279.0	270.3	8.0 (7.3; 8.7)		2004-2022	
																					10.6 (9.7; 11.6)		2004-2017	
																								2018-2022
<b>50-64</b>	<b>N</b>	141	135	153	212	196	206	253	271	329	352	404	476	523	712	710	848	733	859	877				
	<b>CR</b>	15.4	14.5	16.0	21.6	19.5	20.0	24.1	25.3	30.4	32.2	36.6	42.5	46.3	62.4	61.9	73.6	63.4	74.1	75.4				
	<b>ESR2013</b>	15.0	14.1	15.8	21.4	19.4	19.9	24.0	25.2	30.2	32.0	36.5	42.4	46.2	62.6	62.3	74.4	64.7	75.5	77.4	10.9 (10.0; 11.9)		2004-2022	
<b>65+</b>	<b>N</b>	48	34	43	39	55	55	52	70	61	75	62	96	111	106	119	151	126	136	176				
	<b>CR</b>	4.6	3.2	4.1	3.7	5.2	5.2	4.8	6.4	5.5	6.7	5.5	8.3	9.5	9.0	9.9	12.5	10.2	11.0	13.9				
	<b>ESR2013</b>	4.7	3.5	4.3	3.9	5.5	5.4	5.3	6.9	5.8	7.1	5.9	8.8	10.3	9.7	10.7	13.3	11.2	11.8	14.8	7.7 (6.5; 9.0)		2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024